Amicus Therapeutics - Stock Price History | FOLD

Historical daily share price chart and data for Amicus Therapeutics since 2023 adjusted for splits. The latest closing stock price for Amicus Therapeutics as of January 27, 2023 is 12.83.
  • The all-time high Amicus Therapeutics stock closing price was 24.89 on December 22, 2020.
  • The Amicus Therapeutics 52-week high stock price is 13.62, which is 6.2% above the current share price.
  • The Amicus Therapeutics 52-week low stock price is 5.91, which is 53.9% below the current share price.
  • The average Amicus Therapeutics stock price for the last 52 weeks is 10.19.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Amicus Therapeutics Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2022 10.0169 12.1100 12.7500 6.2300 12.2100 5.71%
2021 11.6151 21.7800 23.8600 8.7100 11.5500 -49.98%
2020 14.2237 9.5500 24.8900 6.6300 23.0900 137.06%
2019 11.2103 10.0400 14.4000 7.4800 9.7400 1.67%
2018 13.8221 15.1600 17.1200 8.3800 9.5800 -33.43%
2017 10.3500 5.1300 16.2400 5.1300 14.3900 189.54%
2016 6.9360 9.0300 9.3500 4.5300 4.9700 -48.76%
2015 11.4110 8.6100 18.2300 5.9500 9.7000 16.59%
2014 4.2658 2.4100 8.6100 1.8200 8.3200 254.04%
2013 2.7800 2.8400 4.2200 1.9700 2.3500 -12.31%
2012 5.2648 3.5700 6.8800 2.5300 2.6800 -22.09%
2011 5.3292 4.5600 7.9400 2.1000 3.4400 -26.81%
2010 3.4267 3.8400 4.8000 1.9500 4.7000 18.39%
2009 7.9094 8.0000 12.2700 3.3600 3.9700 -50.25%
2008 11.2884 10.3400 17.9500 7.5000 7.9800 -25.77%
2007 13.8496 14.4300 18.0400 9.5400 10.7500 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.700B $0.306B
Amicus Therapeutics, Inc. is a global patient-centric biotechnology company engaged in the discovery, development and commercialization of a diverse set of novel treatments for patients living with rare metabolic diseases.?The company has one marketed medicine in its portfolio named Galafold which is the first and the only approved oral precision medicine for patients living with Fabry disease, having amenable genetic variants. Migalastat is a potent orally available inhibitor of alpha-Gal A.?The drug was granted an accelerated approval by the FDA for treating adult patients with a confirmed diagnosis of Fabry disease and an amenable genetic variant. Galafold is the first and only oral therapy approved in the EU for the long-term treatment of adolescents with Fabry disease.?The lead pipeline candidate in the company's portfolio is AT-GAA, a differentiated biologic for Pompe disease. The company has one gene-therapy program in its pipeline CLN3, a type of Batten disease, being evaluated in a phase I/II study.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $155.188B 9.47
GSK (GSK) United Kingdom $72.345B 9.01
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.333B 19.34
Ginkgo Bioworks Holdings (DNA) United States $3.395B 0.00
Myovant Sciences (MYOV) United Kingdom $2.604B 0.00
Arcus Biosciences (RCUS) United States $1.672B 25.10
Biohaven (BHVN) United States $1.264B 0.00
Emergent Biosolutions (EBS) United States $0.655B 5.15
ADC Therapeutics SA (ADCT) Switzerland $0.363B 0.00
Ambrx Biopharma (AMAM) United States $0.073B 0.00
Enzo Biochem (ENZ) United States $0.073B 0.00
Gelesis Holdings (GLS) United States $0.027B 0.00
SQZ Biotechnologies (SQZ) United States $0.025B 0.00